Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

Assiut University100 enrolled

Overview

Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy. Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy . Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Epilepsy

Interventions

Memantine HydrochlorideDRUG

Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.

PlaceboDRUG

Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with idiopathic epilepsy. * Normal brain imaging (CT brain). * Patients on anti epileptic drugs more than 6 months. * No more than two fits per month. * Score of Mini mental state examination (10-24), mild and moderate cognitive impairment. * No other medical disorders. Exclusion Criteria: * Progressive neurological diseases. * Abnormal brain imaging (CT brain). * More than two fits per month. * Patients with severe cognitive impairment, score of MMSE less than10. * Patients with severe medical disorders

Locations (1)

Salma Mohmed Fahmy

Asyut, Egypt

Outcomes

Primary Outcomes

Memory Assessment Scale (MAS)

This comprehensive battery assesses short-term, verbal and visual memory functioning.

Time frame: 1.5years

Wechsler Adult Intelligence Scale (WAIS)

Intelligence quotient (IQ) tests are the primary clinical instruments used to measure adult and adolescent intellience.

Time frame: 1.5years

Brief Visuospatial Memory Test-Revised (BVMT-R)

The current revised version of the BVMT, a visual display of six simple figures arranged in a 2 × 3 matrix on an 8 × 11 booklet is shown to participants for three consecutive 10-second trials.

Time frame: 1.5years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.